| |
VA researchers develop biomed innovations in all areas of healthcare, from substance abuse treatments to visual impairment aids and more. License and commercialize VA innovations with no-cost help from TechLink. Learn about available technologies. 
|
|
Today’s Big NewsJul 24, 2024 |
| By Nick Paul Taylor Sage Therapeutics and Biogen have extended the pharma industry’s multi-decade essential tremor losing streak. Three years after tolerability overshadowed efficacy, the partners have given up on SAGE-324 in the indication after failing to reduce tremors in a phase 2 trial designed to address their earlier problems. |
|
|
|
By James Waldron Three months after scoring FDA approval for its hemophilia B gene therapy, Pfizer has posted phase 3 data suggesting it may be able to pull off the same success with a different candidate in hemophilia A. |
By Annalee Armstrong After reaching out to more than 200 companies to partner a Tourette syndrome therapy that showed the ability to beat standard of care last year, Asarina Pharma has come up empty and will fold. |
Sponsored by CSafe Global How is the cold chain adapting to the cell and gene therapy boom? Emilio Frattaruolo, Vice President of Cell and Gene Therapies at CSafe, discusses the logistical challenges and innovations shaping the future of these revolutionary treatments. |
|
Cryoport Systems' temperature-controlled supply chain solutions, including biostorage, drug labelling, kit production, cryopreservation & consulting were built with scalability in mind, Enabling The Outcome™️ for patients around the world. Learn More. 
|
|
By Darren Incorvaia Novartis has had some bad luck with bispecific antibodies in the past, but judging by the pharma's latest deal it still has faith in the modality. |
Sponsored by InMed Pharmaceuticals InMed’s INM-901 Demonstrates Potential as a Multi-factorial Approach to Treating Alzheimer’s Disease |
By Annalee Armstrong Pinetree Therapeutics will help AstraZeneca plant some trees in its pipeline with a new pact to develop a preclinical EGFR degrader worth $45 million upfront for the small biotech. |
By James Waldron Actuate’s upcoming IPO may be on the smaller side in comparison to its biotech peers that have publicaly listed this year, but that hasn’t stopped the cancer-focused company from continuing to tweak its offering. |
By Darren Incorvaia When it comes to developing new pain drugs, the placebo effect is a powerful but baffling force. Researchers have successfully mapped the neural circuits responsible for placebo pain relief in mice. |
By Gabrielle Masson,Darren Incorvaia,Max Bayer We really didn't want to have to create another Layoff Tracker this year. But here we are, launching the third annual iteration tracking biopharma layoffs. |
By Gabrielle Masson,Annalee Armstrong,Darren Incorvaia,Max Bayer Welcome to Fierce Biotech's Fundraising Tracker, 2024's version. |
By Kevin Dunleavy An FDA advisory committee will discuss AstraZeneca’s application for Imfinzi in early-stage non-small cell lung cancer. The agency is asking external experts to weigh in on whether a new trial is needed to determine the contributions of the therapy on either end of surgery. |
By Noah Tong A contentious hearing between PBM CEOs and the House Commitee on Oversight and Accountability reinforced recent federal angst toward pharmacy benefit managers, but little new ground was made. |
Fierce podcasts Don’t miss an episode |
| In February, Novo Holdings announced a $16.5 billion deal to acquire Catalent, and this week on "The Top Line," we explore the current state and implications of the proposed buyout. |
|
|---|
|
|
|
September 25-27, 2024 | Philadelphia, PA Join the Fierce Clinical Summit, the premier event for clinical research and trial management. Explore topics in Clinical Operations, Quality, and DCT & Technology. Learn, network, and connect with peers to advance industry standards and innovations in clinical trials. Secure your pass today! 
|
|
Whitepaper Download the white paper to learn how this innovative solution can help optimize your mAb production processes. The findings demonstrate the system's robust capability to sustain strong cell growth and high productivity, facilitating a smooth transition from laboratory to production scale. Sponsored by: Thermo Fisher Scientific |
Whitepaper In this white paper, Lonza experts delve into the common challenges encountered by ADC developers. They explore new drug product capabilities in relation to cytotoxic drug development and manufacturing, therefore fully completing Lonza’s integrated ADC offering. Further, they discuss how this end-to-end approach can significantly accelerate the timeline to investigational new drug filing and beyond. Read this white paper to learn more. Sponsored by: Lonza |
Whitepaper The definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
Whitepaper In a complex industry like biopharma, being a “Best Practice Organization” (BPO) is essential to success. But what is a BPO & how do you build one? This eBook provides the answers. Sponsored by: Blue Matter, strategic consultants in the life sciences |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
